581 related articles for article (PubMed ID: 12911529)
1. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype.
Nakao S; Kodama C; Takenaka T; Tanaka A; Yasumoto Y; Yoshida A; Kanzaki T; Enriquez AL; Eng CM; Tanaka H; Tei C; Desnick RJ
Kidney Int; 2003 Sep; 64(3):801-7. PubMed ID: 12911529
[TBL] [Abstract][Full Text] [Related]
2. Fabry disease in hemodialysis patients in southern Brazil: prevalence study and clinical report.
Porsch DB; Nunes AC; Milani V; Rossato LB; Mattos CB; Tsao M; Netto C; Burin M; Pereira F; Matte U; Giugliani R; Barros EJ
Ren Fail; 2008; 30(9):825-30. PubMed ID: 18925518
[TBL] [Abstract][Full Text] [Related]
3. Significance of screening for Fabry disease among male dialysis patients.
Ichinose M; Nakayama M; Ohashi T; Utsunomiya Y; Kobayashi M; Eto Y
Clin Exp Nephrol; 2005 Sep; 9(3):228-32. PubMed ID: 16189631
[TBL] [Abstract][Full Text] [Related]
4. Alpha-galactosidase A activity levels in Turkish male hemodialysis patients.
Kalkan Uçar S; Sozmen E; Duman S; Başçi A; Çoker M
Ther Apher Dial; 2012 Dec; 16(6):560-5. PubMed ID: 23190516
[TBL] [Abstract][Full Text] [Related]
5. Screening for Fabry disease in patients undergoing dialysis for chronic renal failure in Turkey: identification of new case with novel mutation.
Okur I; Ezgu F; Biberoglu G; Tumer L; Erten Y; Isitman M; Eminoglu FT; Hasanoglu A
Gene; 2013 Sep; 527(1):42-7. PubMed ID: 23756194
[TBL] [Abstract][Full Text] [Related]
6. Identification of a novel mutation and prevalence study for fabry disease in Japanese dialysis patients.
Nishino T; Obata Y; Furusu A; Hirose M; Shinzato K; Hattori K; Nakamura K; Matsumoto T; Endo F; Kohno S
Ren Fail; 2012; 34(5):566-70. PubMed ID: 22563919
[TBL] [Abstract][Full Text] [Related]
7. Identification of Fabry's disease by the screening of alpha-galactosidase A activity in male and female hemodialysis patients.
Tanaka M; Ohashi T; Kobayashi M; Eto Y; Miyamura N; Nishida K; Araki E; Itoh K; Matsushita K; Hara M; Kuwahara K; Nakano T; Yasumoto N; Nonoguchi H; Tomita K
Clin Nephrol; 2005 Oct; 64(4):281-7. PubMed ID: 16240899
[TBL] [Abstract][Full Text] [Related]
8. High-throughput screening identified disease-causing mutants and functional variants of α-galactosidase A gene in Japanese male hemodialysis patients.
Doi K; Noiri E; Ishizu T; Negishi K; Suzuki Y; Hamasaki Y; Honda K; Fujita T; Tsukimura T; Togawa T; Saito S; Sakuraba H
J Hum Genet; 2012 Sep; 57(9):575-9. PubMed ID: 22695894
[TBL] [Abstract][Full Text] [Related]
9. Fabry disease. A case report.
Kotnik J; Kotnik F; Desnick RJ
Acta Dermatovenerol Alp Pannonica Adriat; 2005 Mar; 14(1):15-9. PubMed ID: 15818441
[TBL] [Abstract][Full Text] [Related]
10. A missense mutation, A156T, in the alpha-galactosidase A gene causes typical Fabry disease.
Konoshita T; Mutoh H; Yokoi T; Koni I; Miyamori I; Mabuchi H
Clin Nephrol; 2001 Mar; 55(3):243-7. PubMed ID: 11316246
[TBL] [Abstract][Full Text] [Related]
11. [Evaluation of patients with Fabry disease in Argentina].
AADELFA (Asociación Argentina de estudio de enfermedad de Fabry y otras enfermedades lisosomales)
Medicina (B Aires); 2010; 70(1):37-43. PubMed ID: 20228022
[TBL] [Abstract][Full Text] [Related]
12. Targeted Screening of Fabry Disease in Male Hemodialysis Patients in Brazil Highlights Importance of Family Screening.
Silva CA; Barreto FC; Dos Reis MA; Moura Junior JA; Cruz CM
Nephron; 2016; 134(4):221-230. PubMed ID: 27576502
[TBL] [Abstract][Full Text] [Related]
13. Japanese patients with Fabry disease predominantly showing cardiac and neurological manifestation with novel missense mutation: R220P.
Fukutomi M; Tanaka N; Uchinoumi H; Kanemoto M; Nakao F; Yamada J; Kamei T; Takenaka T; Fujii T
J Cardiol; 2013 Jul; 62(1):63-9. PubMed ID: 23608164
[TBL] [Abstract][Full Text] [Related]
14. Fabry disease in patients with end-stage renal failure: the potential benefits of screening.
Bekri S; Enica A; Ghafari T; Plaza G; Champenois I; Choukroun G; Unwin R; Jaeger P
Nephron Clin Pract; 2005; 101(1):c33-8. PubMed ID: 15886492
[TBL] [Abstract][Full Text] [Related]
15. An atypical variant of Fabry's disease in men with left ventricular hypertrophy.
Nakao S; Takenaka T; Maeda M; Kodama C; Tanaka A; Tahara M; Yoshida A; Kuriyama M; Hayashibe H; Sakuraba H
N Engl J Med; 1995 Aug; 333(5):288-93. PubMed ID: 7596372
[TBL] [Abstract][Full Text] [Related]
16. The frequency of Fabry disease with the E66Q variant in the α-galactosidase A gene in Japanese dialysis patients: a case report and a literature review.
Kikumoto Y; Sugiyama H; Morinaga H; Inoue T; Takiue K; Kitagawa M; Saito D; Takatori Y; Kinomura M; Kitamura S; Akagi S; Sada K; Nakao K; Maeshima Y; Kitayama H; Makino H
Clin Nephrol; 2012 Sep; 78(3):224-9. PubMed ID: 22874111
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of Fabry disease among Turkish dialysis patients: Data from hemodialysis centers in Bursa province.
Sayilar EI; Ayar Y; Yavuz M
Clin Nephrol; 2016 Mar; 85(3):165-72. PubMed ID: 26833297
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of Fabry Disease in Korean Men with Left Ventricular Hypertrophy.
Kim WS; Kim HS; Shin J; Park JC; Yoo HW; Takenaka T; Tei C
J Korean Med Sci; 2019 Feb; 34(7):e63. PubMed ID: 30804731
[TBL] [Abstract][Full Text] [Related]
19. Anderson-Fabry disease: a multiorgan disease.
Tuttolomondo A; Pecoraro R; Simonetta I; Miceli S; Pinto A; Licata G
Curr Pharm Des; 2013; 19(33):5974-96. PubMed ID: 23448451
[TBL] [Abstract][Full Text] [Related]
20. Phenotypical characterization of α-galactosidase A gene mutations identified in a large Fabry disease screening program in stroke in the young.
De Brabander I; Yperzeele L; Ceuterick-De Groote C; Brouns R; Baker R; Belachew S; Delbecq J; De Keulenaer G; Dethy S; Eyskens F; Fumal A; Hemelsoet D; Hughes D; Jeangette S; Nuytten D; Redondo P; Sadzot B; Sindic C; Sheorajpanday R; Thijs V; Van Broeckhoven C; De Deyn PP
Clin Neurol Neurosurg; 2013 Jul; 115(7):1088-93. PubMed ID: 23219219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]